MicroRNA mimics can distort physiological microRNA effects on immune checkpoints by triggering an antiviral interferon response

References

• Lee RC, Feinbaum RL, Ambros V. The C. elegans heterochronic gene lin-4 encodes small RNAs with antisense complementarity to lin-14. Cell. 1993 Dec 3; 75(5):843–854.
   PubMed Web of Science ®Google Scholar
• Montano M. MICRORNAs: miRRORS OF HEALTH AND DISEASE. Transl Res J Lab Clin Med. 2011 Apr;157(4):157–162.
   Google Scholar
• Bartel DP. MicroRNAs: genomics, biogenesis, mechanism, and function. Cell. 2004 Jan 23; 116(2):281–297.
   PubMed Web of Science ®Google Scholar
• Paul P, Chakraborty A, Sarkar D, et al. Interplay between miRNAs and human diseases. J Cell Physiol. 2018;233(3):2007–2018.
   PubMed Web of Science ®Google Scholar
• Di Leva G, Garofalo M, Croce CM. MicroRNAs in cancer. Annu Rev Pathol. 2014;9(1):287–314.
   PubMedGoogle Scholar
• Peng Y, Croce CM. The role of MicroRNAs in human cancer. Signal Transduct Target Ther. 2016 Jan 28;1(1):1–9.
   Google Scholar
• Avvari S, Prasad D, Khan IA. Role of MicroRNAs in Cell Growth Proliferation and Tumorigenesis. Prasad D, Santosh Sushma P,editors. Role of MicroRNAs in cancers [Internet]. Singapore:Springer Nature.2022 cited 2022 Jun 20 37–51.Available from 10.1007/978-981-16-9186-7_3.
   Google Scholar
• Magee P, Shi L, Garofalo M. Role of microRNAs in chemoresistance. Ann Transl Med. 2015 Dec;3(21):332.
   PubMed Web of Science ®Google Scholar
• Shirjang S, Mansoori B, Asghari S, et al. MicroRNAs in cancer cell death pathways: apoptosis and necroptosis. Free Radic Biol Med. 2019 Aug 1;139:1–15.
   PubMed Web of Science ®Google Scholar
• Zaravinos A. The regulatory role of MicroRNAs in EMT and cancer. J Oncol. 2015;2015:865816.
   PubMed Web of Science ®Google Scholar
• Ribatti D, Tamma R, Annese T. Epithelial-mesenchymal transition in cancer: a historical overview. Transl Oncol. 2020 Jun;13(6):100773.
   PubMed Web of Science ®Google Scholar
• Kahlert C, Lahes S, Radhakrishnan P, et al. Overexpression of ZEB2 at the invasion front of colorectal cancer is an independent prognostic marker and regulates tumor invasion in vitro. Clin Cancer Res. 2011 Dec 18 17(24):7654–7663.
   PubMed Web of Science ®Google Scholar
• Kahlert C, Klupp F, Brand K, et al. Invasion front-specific expression and prognostic significance of microRNA in colorectal liver metastases. Cancer Sci. 2011;102(10):1799–1807.
   PubMed Web of Science ®Google Scholar
• Jiang Y, Zhan H. Communication between EMT and PD-L1 signaling: new insights into tumor immune evasion. Cancer Lett. 2020 Jan 1; 468:72–81
   PubMed Web of Science ®Google Scholar
• Soundararajan R, Fradette JJ, Konen JM, et al. Targeting the interplay between epithelial-to-mesenchymal-transition and the immune system for effective immunotherapy. Cancers (Basel). 2019 May;11(5):714.
   PubMed Web of Science ®Google Scholar
• Thompson JC, Hwang WT, Davis C, et al. Gene signatures of tumor inflammation and epithelial-to-mesenchymal transition (EMT) predict responses to immune checkpoint blockade in lung cancer with high accuracy. Lung Cancer Amst Neth. 2020 Jan;139:1–8.
   PubMed Web of Science ®Google Scholar
• Mahmoudian RA, Mozhgani S, Abbaszadegan MR, et al. Correlation between the immune checkpoints and EMT genes proposes potential prognostic and therapeutic targets in ESCC. J Mol Histol. 2021 Jun;52(3):597–609.
   PubMed Web of Science ®Google Scholar
• Pitt JM, Vétizou M, Daillère R, et al. Resistance mechanisms to immune-checkpoint blockade in cancer: tumor-intrinsic and -extrinsic factors. Immunity. 2016 Jun 21 44(6):1255–1269.
   PubMed Web of Science ®Google Scholar
• He X, Xu C. Immune checkpoint signaling and cancer immunotherapy. Cell Res. 2020 Aug;30(8):660–669.
   PubMed Web of Science ®Google Scholar
• Iwai Y, Ishida M, Tanaka Y, et al. Involvement of PD-L1 on tumor cells in the escape from host immune system and tumor immunotherapy by PD-L1 blockade. Proc Natl Acad Sci U S A. 2002 Sep 17; 99(19):12293–12297.
   PubMed Web of Science ®Google Scholar
• Yasinska IM, Sakhnevych SS, Pavlova L, et al. The Tim-3-galectin-9 pathway and its regulatory mechanisms in human breast cancer. Front Immunol. 2019;10:1594.
   PubMed Web of Science ®Google Scholar
• Uyttenhove C, Pilotte L, Théate I, et al. Evidence for a tumoral immune resistance mechanism based on tryptophan degradation by indoleamine 2,3-dioxygenase. Nat Med. 2003 Oct;9(10):1269–1274.
   PubMed Web of Science ®Google Scholar
• Holmgaard RB, Zamarin D, Munn DH, et al. Indoleamine 2,3-dioxygenase is a critical resistance mechanism in antitumor T cell immunotherapy targeting CTLA-4. J Exp Med. 2013 Jun 10; 210(7):1389–1402.
   PubMed Web of Science ®Google Scholar
• Park SM, Gaur AB, Lengyel E, et al. The miR-200 family determines the epithelial phenotype of cancer cells by targeting the E-cadherin repressors ZEB1 and ZEB2. Genes Dev. 2008 Apr 1; 22(7):894–907.
   PubMed Web of Science ®Google Scholar
• Mongroo PS, Rustgi AK. The role of the miR-200 family in epithelial-mesenchymal transition. Cancer Biol Ther. 2010 Aug 1; 10(3):219–222.
   PubMed Web of Science ®Google Scholar
• Chen L, Gibbons DL, Goswami S, et al. Metastasis is regulated via microRNA-200/ZEB1 axis control of tumour cell PD-L1 expression and intratumoral immunosuppression. Nat Commun. 2014 Oct 28 5(1):5241.
   PubMedGoogle Scholar
• Cao L, Bridle KR, Shrestha R, et al. CD73 and PD-L1 as potential therapeutic targets in gallbladder cancer. Int J Mol Sci. 2022 Jan 29; 23(3):1565.
   PubMed Web of Science ®Google Scholar
• Oh DY, He AR, Qin S, et al. A phase 3 randomized, double-blind, placebo-controlled study of durvalumab in combination with gemcitabine plus cisplatin (GemCis) in patients (pts) with advanced biliary tract cancer (BTC): TOPAZ-1. J Clin Oncol. 2022 Feb;40(4_suppl):378.
   Web of Science ®Google Scholar
• Miyagiwa M, Ichida T, Tokiwa T, et al. A new human cholangiocellular carcinoma cell line (HuCC-T1) producing carbohydrate antigen 19/9 in serum-free medium. Vitro Cell Dev Biol J Tissue Cult Assoc. 1989 Jun;25(6): 503–510.
   PubMed Web of Science ®Google Scholar
• Kusaka Y, Tokiwa T, Sato J. Establishment and characterization of a cell line from a human cholangiocellular carcinoma. Res Exp Med Z Gesamte Exp Med Einschl Exp Chir. 1988;188(5):367–375
   Google Scholar
• Yamada N, Chung Y, Ohtani H, et al. Establishment and characterization of a new human gallbladder carcinoma cell line (OCUG-1) producing TA-4. Int J Oncol. 1997 Jun 1 10(6):1251–1255.
   PubMed Web of Science ®Google Scholar
• Homma S, Nagamori S, Fujise K, et al. Human bile duct carcinoma cell line producing abundant mucin in vitro. Gastroenterol Jpn. 1987 Aug;22(4):474–479.
   PubMedGoogle Scholar
• Homma S, Hasumura S, Nagamori S, et al. Establishment and characterization of a human gall bladder carcinoma cell line NOZ. Hum Cell. 1988 Mar;1(1):95–97.
   PubMedGoogle Scholar
• Sripa B, Leungwattanawanit S, Nitta T, et al. Establishment and characterization of an opisthorchiasis-associated cholangiocarcinoma cell line (KKU-100). World J Gastroenterol. 2005 Jun 14 11(22):3392–3397.
   PubMed Web of Science ®Google Scholar
• Maruyama M, Kobayashi N, Westerman KA, et al. Establishment of a highly differentiated immortalized human cholangiocyte cell line with SV40T and hTERT. Transplantation. 2004 Feb 15 77(3):446–451.
   PubMed Web of Science ®Google Scholar
• Saijyo S, Kudo T, Suzuki M, et al. Establishment of a new extrahepatic bile duct carcinoma cell line, TFK-1. Tohoku J Exp Med. 1995 Sep;177(1):61–71.
   PubMed Web of Science ®Google Scholar
• Posch F, Prinz F, Balihodzic A, et al. MiR-200c-3p modulates cisplatin resistance in biliary tract cancer by ZEB1-independent mechanisms. Cancers (Basel). 2021 Aug 8 13(16):3996.
   PubMed Web of Science ®Google Scholar
• Orzalli MH, Kagan JC. Apoptosis and necroptosis as host defense strategies to prevent viral infection. Trends Cell Biol. 2017 Nov;27(11):800–809.
   PubMed Web of Science ®Google Scholar
• Kang E, Jung SC, Nam SK, et al. Tissue miR-200c-3p and circulating miR-1290 as potential prognostic biomarkers for colorectal cancer. Sci Rep. 2022 Feb 10 12(1):2295.
   PubMed Web of Science ®Google Scholar
• Anastasiadou E, Ceccarelli S, Messina E, et al. MiR-200c-3p maintains stemness and proliferative potential in adipose-derived stem cells by counteracting senescence mechanisms. PloS One. 2021;16(9):e0257070.
   PubMed Web of Science ®Google Scholar
• Anastasiadou E, Messina E, Sanavia T, et al. MiR-200c-3p contrasts PD-L1 induction by combinatorial therapies and slows proliferation of epithelial ovarian cancer through downregulation of β-catenin and c-myc. Cells. 2021 Mar 1 10(3):519.
   PubMed Web of Science ®Google Scholar
• Noman MZ, Janji B, Abdou A, et al. The immune checkpoint ligand PD-L1 is upregulated in EMT-activated human breast cancer cells by a mechanism involving ZEB-1 and miR-200. Oncoimmunology. 2017 Jan 23 6(1):e1263412.
   PubMed Web of Science ®Google Scholar
• Jin HY, Gonzalez-Martin A, Miletic AV, et al. Transfection of microRNA mimics should be used with caution. Front Genet. 2015;6:340.
   PubMed Web of Science ®Google Scholar
• Thomson DW, Bracken CP, Szubert JM, et al. On measuring miRNAs after transient transfection of mimics or antisense inhibitors. PLoS ONE. 2013 Jan 24; 8(1):e55214.
   PubMed Web of Science ®Google Scholar
• Goldgraben MA, Russell R, Rueda OM, et al. Double-stranded microRNA mimics can induce length- and passenger strand-dependent effects in a cell type-specific manner. RNA N Y N. 2016 Feb;22(2):193–203.
   PubMed Web of Science ®Google Scholar
• Tsai SY, Segovia JA, Chang TH, et al. Regulation of TLR3 activation by S100A9. J Immunol. 2015 Nov 1 195(9):4426–4437.
   PubMed Web of Science ®Google Scholar
• Kleinman ME, Yamada K, Takeda A, et al. Sequence- and target-independent angiogenesis suppression by siRNA via TLR3. Nature. 2008 Apr 3 452(7187):591–597.
   PubMed Web of Science ®Google Scholar
• Kleinman ME, Kaneko H, Cho WG, et al. Short-interfering RNAs induce retinal degeneration via TLR3 and IRF3. Mol Ther J Am Soc Gene Ther. 2012 Jan;20(1):101–108.
   PubMed Web of Science ®Google Scholar
• Cho WG, Albuquerque RJC, Kleinman ME, et al. Small interfering RNA-induced TLR3 activation inhibits blood and lymphatic vessel growth. Proc Natl Acad Sci U S A. 2009 Apr 28 106(17):7137–7142.
   PubMed Web of Science ®Google Scholar
• Diener C, Keller A, Meese E. Emerging concepts of miRNA therapeutics: from cells to clinic. Trends Genet. 2022 Jun 1; 38(6):613–626.
   PubMed Web of Science ®Google Scholar
• Beg MS, Brenner AJ, Sachdev J, et al. Phase I study of MRX34, a liposomal miR-34a mimic, administered twice weekly in patients with advanced solid tumors. Invest New Drugs. 2017 Apr;35(2):180–188.
   PubMed Web of Science ®Google Scholar
• Hong DS, Kang YK, Borad M, et al. Phase 1 study of MRX34, a liposomal miR-34a mimic, in patients with advanced solid tumours. Br J Cancer. 2020 May;122(11):1630–1637.
   PubMed Web of Science ®Google Scholar
• Zhang Z, Huang Q, Yu L, et al. The role of miRNA in tumor immune escape and miRNA-based therapeutic strategies. Front Immunol. Internet]. 2022 cited 2022 Jun 25;12. Available from: 10.3389/fimmu.2021.807895
   Web of Science ®Google Scholar